Accepted_test

Although a number of drug-eluting coatings for vascular stents have been developed and are in commercial use, more efficient stent coatings and drug delivery systems are needed. Scaffolds, intended for coating vascular stents and contain drugs (paclitaxel and sirolimus) were produced by electrospinning from a solution of polycaprolactone (PCL) and human serum albumin (HSA), HFIP, dimethylsulfoxide (DMSO). Drug release kinetics from scaffolds has been studied. PCL-based scaffolds containing both HSA and DMSO are the most promising coatings for vascular stents with long-term drug release. Regardless of the fiber composition, scaffold elongation has no significant effect on the drug release kinetic. It has been shown that the arterial wall effectively retains drugs. The drug accumulation in the arterial wall contributes to the long-term maintenance of subcitotoxic concentrations of drugs in the arterial wall and allows reducing the dose of drugs added into the stent coating. To solve the problem of drug washing out by blood flow, it was proposed to use scaffolds containing a barrier layer filled with activated carbon (AC). It has been shown that AC in the barrier layer adsorbs drugs well, while carbon-filled scaffolds are non-toxic, well compatible with eukaryotic cells and have good hemocompatibility. Scaffolds with AC-filled layer can be used for the manufacture of stent coatings, vascular prostheses, and other implantable tubular structures. This structure of the material makes it possible to decrease the drug concentration, reduce their systemic delivery and increase the effectiveness of medical devices.